Topiramate capsules had annual sales of $68.8 million in the US. (Representative)
New Delhi:
Zydus Lifesciences today said it has received approval from the US health regulator to sell Topiramate Extended-Release Capsules, which is used to prevent and control seizures in people with epilepsy, in the US market.
The company said it has received final approval from the US Food and Drug Administration (USFDA) to market the product in multiple strengths.
Topiramate extended-release capsules are indicated to prevent and control seizures in people with epilepsy. It can also be used to prevent migraine headaches.
The drug will be manufactured at the group’s manufacturing facility in the Ahmedabad SEZ, Zydus said in a statement.
According to IQVIA data, annual sales in the US market for topiramate extended-release capsules were $68.8 million.
(Except for the headline, this story has not been edited by NDTV staff and is published from a syndicated feed.)
featured video of the day
Retail inflation eases to 6.77% in October, lowest in 3 months
